Anupriya Singhal

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Anupriya Singhal
Dec 25, 2024, 18:18 | Blog
A classical epithelial cancer cell state drives resistance to KRAS inhibition in Pancreatic Cancer - NCI Division of Cancer Biology
NCI Division of Cancer Biology shared a post on X: “Using reporter systems and preclinical…
Nov 5, 2024, 11:14 | Insight
Eileen M. O’Reilly: Adjuvant mFOLFIRINOX for Resected Pancreatic Adenocarcinoma
Eileen M. O’Reilly, Oncologist at Memorial Sloan Kettering Cancer Centre, shared on X: “Adjuvant mFOLFIRINOX…
Oct 29, 2024, 09:39 | Insight
Anirban Maitra: Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC) led by Eileen M O’Reilly
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared…
Sep 24, 2024, 14:18 | Insight
Sergio Cifuentes: The Clinico-genomic Landscape and Outcomes of KRAS G12C–Mutated Pancreatic Cancer
Sergio Cifuentes, Cancer Research Project Manager at CENEIT Mexico, shared on X: "Check out my…
Jul 14, 2024, 04:21 | Insight
Elizabeth McKenna: 4 papers with variations on the theme of cancer cell plasticity as a mechanism of resistance to KRAS inhibition
Norbert Kraut, Global Head of Cancer Research Boehringer Ingelheim, shared a post by Elizabeth McKenna,…
Jul 10, 2024, 07:19 | Insight
Tuomas Tammela: Co-targeting classical cells and KRAS augments response in pancreas cancer
Tuomas Tammela, Associate Member at Memorial Sloan Kettering Cancer Center, shared on X: "New Paper!…
Apr 29, 2024, 08:17 | Insight
Bob Li: It was a privilege to lead the first international clinical trial to crack KRAS
Bob Li, Chief Scientific Officer of MSK Direct at Memorial Sloan Kettering Cancer Center, shared…
All: 7 Posts: 1 - 100
Special Coverage